Drug intelligence / Profile preview

VNX004

Development stage: Preclinical
Lead developer: Vaneltix Pharma
Modality: Small Molecules
Administration: Topical

Overview

VNX004 is a preclinical-stage topical formulation being developed by Vaneltix Pharma for the treatment of bladder pain and general topical pain relief. The drug utilizes alkalinized lidocaine as its active ingredient, a local anesthetic that works by blocking voltage-gated sodium channels to inhibit the conduction of pain impulses. VNX004 leverages the technology and intellectual property of Vaneltix's lead product, Alenura, but adapts the alkalinized lidocaine into novel topical dosage forms for indications both within and beyond urology.

Other names: alkalinized lidocaine topical formulation

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on VNX004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VNX004.

Explore the full profile